DOI: http://dx.doi.org/10.18203/2394-6040.ijcmph20213013

Cholangiocarcinoma in South India: unprecedented, unanticipated and underreported

Priya Nair, Harshavardhan Rao B., Anoop K. Koshy, Surendran Sudhindran, K. Pavithran, Rama P. Venu

Abstract


Background: The incidence of CCA in India is on the rise especially in Kerala. However, the clinical profile and outcome of these patients has never been reported. The aim of this study was to identify region specific epidemiological trends and natural history of CCA in Kerala.

Methods: This was a single centre, hospital based epidemiology study where incident cases of CCA from January 2014 to August 2016 were studied. Patient demographics and relevant clinical and laboratory data, imaging studies and treatment, were recorded in a predesigned Performa.

Results: A total of 137 patients (mean age 62.92 ± 12.5 years, M:F=1.2) were studied of which 109 patients had Hilar CCA (pCCA), 16 patients had Distal CCA (dCCA) and 12 patients had Intrahepatic CCA (iCCA). A majority of patients were from coastal areas and rubber plantations. Known risk factors were absent in our patients. Bismuth Type IV disease was seen in 55 patients (50.5%). Most intrahepatic CCA (iCCA) (7/12) patients had stage IV disease at presentation. Curative resection was possible in 17/38 patients (44.7%). Patients who underwent treatment with a curative intent were younger with less advanced disease and therefore, had a significant 3 month, 6 month and 1 year survival advantage (p<0.05). The overall 1-year mortality was 66.1% (91/137). The 30-day post-op mortality was 4.3%.

Conclusions: This study highlights a unique epidemiological pattern in our patients characterised by absence of known risk factors and unique geographic clusters. Palliative chemotherapy showed a significant survival benefit in this study which needs further validation.

 


Keywords


Cholangiocarcinoma, Biliary drainage, Hepatic resection

Full Text:

PDF

References


Global Burden of Disease Cancer Collaboration. The Global Burden of Cancer 2013. JAMA Oncol. 2015;1(4):505-27.

Banales JM, Cardinale V, Carpino G, Marzioni M, Anderse JB, Invernizzi P, Alvaro D. Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nature Reviews. Gastroenterology & Hepatology. 2016;13(5):261-80.

Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet. 2014;383(9935):2168-79.

Gatto M, Bragazzi MC, Semeraro R, Napoli C, Gentile R, Torrice A, et al. Cholangiocarcinoma: update and future perspectives. Dig Liver Dis. 2010;42(4):253-60.

Patel T. Cholangiocarcinoma. Nat Clin Pract Gastroenterol Hepatol. 2006;3(1):33-42.

Shaib Y, El-Serag HB. The epidemiology of cholangiocarcinoma. Semin Liver Dis. 2004;24(2):115-25.

Blechacz BR, Gores GJ. Cholangiocarcinoma. Clin Liver Dis. 2008;12(1):131-50.

Sripa B, Pairojkul C. Cholangiocarcinoma: lessons from Thailand. Curr Opin Gastroenterol. 2008;24(3):349-56.

Welzel TM, et al. Risk factors for intrahepatic and extrahepaticcholangiocarcinoma in the United States: a population-based case-control study. ClinGastroenterol. Hepatol. 2007;5:1221-8.

Tyson GL, El-Serag HB. Risk factors for cholangiocarcinoma. Hepatology. 2011;54:173-84.

Khan SA, Toledano MB, Taylor-Robinson SD. Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. HPB (Oxford). 2008;10(2):77-82.

Jung MY, Shin HR, Lee CU, Y SS, Lee SW, Park BC. A study of the ratio of hepatocellular carcinoma over cholangiocarcinoma and their risk factors. J Pusan Med Assoc. 1993;29:29-37.

Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology. 2001;33:1353-7.

McGlynn KA, Tarone RE, El-Serag HB. A comparison of trends in the incidence of hepatocellular carcinoma and intrahepatic cholangiocarcinoma in the United States. Cancer Epidemiol Biomarkers Prev. 2006;15:1198-203.

West J, Wood H, Logan RF, Quinn M, Aithal GP. Trends in the incidence of primary liver and biliary tract cancers in England and Wales 1971–2001. Br J Cancer. 2006;94:1751-8.

Patel T. Cholangiocarcinoma—controversies and challenges. Nat Rev Gastroenterol Hepatol. 2011;8(4):189-200.

Shin HR, Oh JK, Lim MK, Shin A, Kong HJ, Jung KW, et al. Descriptive epidemiology of cholangiocarcinoma and clonorchiasis in Korea. J Korean Med Sci. 2010;25(7):1011-6.

Honjo S, Srivatanakul P, Sriplung H, Kikukawa H, Hanai S, Uchida K, et al. Genetic and environmental determinants of risk for cholangiocarcinoma via Opisthorchisviverrini in a densely infested area in NakhonPhanom, northeast Thailand. Int J Cancer. 2005;117(5):854-60.

Palmer WC, Patel T. Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma. J Hepatol. 2012;57(1):69-76.

Donato F, Gelatti U, Tagger A. Intrahepatic cholangiocarcinoma and hepatitis C and B virus infection, alcohol intake, and hepatolithiasis: a case-control study in Italy. Cancer Causes Control. 2001;12:959-64.

El-Serag HB, Engels EA, Landgren O. Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: a population-based study of U.S. veterans. Hepatology. 2009;49:116-23.

Lee TY, Lee SS, Jung SW. Hepatitis B virus infection and intrahepatic cholangiocarcinoma in Korea: a case-control study. Am J Gastroenterol. 2008;103:1716-20.

Zhou YM, Yin ZF, Yang JM. Risk factors for intrahepatic cholangiocarcinoma: a case control study in China. World J Gastroenterol. 2008;14:632-35.

Doherty B, Namboodiri VE, Palmer WC. Update on the Diagnosis and Treatment of Cholangiocarcinoma. Curr Gastroenterol Rep. 2017;19:2.

Tillich M. Multiphasic helical CT in diagnosis and staging of hilarcholangiocarcinoma. AJR Am J Roentgenol. 1998;171(3):651-8.

Vilgrain V. Staging cholangiocarcinoma by imaging studies. HPB (Oxford). 2008;10(2):106-9.

Rizvi S, Gores GJ. Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology. 2013;145(6):1215-29.

Morise Z. Surgery and chemotherapy for intrahepatic cholangiocarcinoma. World J Hepatol. 2010;2(2):58-64.

Yoh T, Hatano E, Nishio T. Significant Improvement in Outcomes of Patients with Intrahepatic Cholangiocarcinoma after Surgery. World J Surg. 2016;40:2229-36.

Endo I, Gonen M, Yopp AC. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg. 2008;248:84-96.

Valle J, Wasan H, Palmer DH. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273-81.

Lee J, Park SH, Chang HM. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2012;13:181-8.